LEVOSIMENDAN to Facilitate Weaning From ECMO in Severe Cardiogenic Shock Patients
Conditions: Cardiogenic Shock; Extracorporeal Membrane Oxygenation Complication Interventions: Drug: Levosimendan; Drug: Placebo of Levosimendan Sponsor: Assistance Publique - Hôpitaux de Paris Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials